PDL BioPharma, Inc.
http://www.pdl.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From PDL BioPharma, Inc.
Biogen Chases Fresenius After Revealing EU Tocilizumab Nod
Ahead of the EMA’s CHMP publishing its April meeting highlights, Biogen has revealed a positive opinion for its Tofidence biosimilar tocilizumab rival to RoActemra. However, Fresenius already has a version on the market.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
Bangers In MASH: How Rezdiffra's Rivals Stack Up
A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Eos Biotechnology, Inc.
- LENSAR, Inc.
- Noden Pharma DAC
- Noden USA
- Protein Design Labs, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice